Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
University of Nebraska
National Institutes of Health Clinical Center (CC)
Travera Inc
Washington University School of Medicine
Jonsson Comprehensive Cancer Center
Instituto do Cancer do Estado de São Paulo
UNICANCER
Travera Inc
University of Maryland, College Park
The Affiliated Hospital of Qingdao University
SCG Cell Therapy Pte. Ltd.
University of Maryland, College Park
HRYZ Biotech Co.
The Affiliated Hospital of Qingdao University
National Institutes of Health Clinical Center (CC)
Region Jönköping County
Xencor, Inc.
Institut de Cancérologie de Lorraine
Karolinska Institutet
Abramson Cancer Center at Penn Medicine
Boston Medical Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Oryx GmbH & Co. KG
Alliance for Clinical Trials in Oncology
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
OHSU Knight Cancer Institute
Emory University
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Hoag Memorial Hospital Presbyterian